Preprint record
In December 2019 SARS CoV 2 emerged in Wuhan, China, leading to a pandemic in March 2020. Although clinical presentation of COVID 19 ranges from no symptoms to acute respiratory and multiorgan failure, the vast majority of the patients only experience flu like symptoms. However because of highly contagious nature of the disease, overall COVID 19 is considered a global health burden. Since ACE2, TMPRSS2 expressing cells are the potential hosts for the virus, inhibiting TMPRSS2 by clinically proven protease inhibitors Bromhexine, Aprotinin, Camostat and Nafamostat are suggested as potential treatments for COVID 19.
Arsalan Azimi (May 19, 2020). TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID 19.. Frenxiv. https://doi.org/10.31226/osf.io/a3rvm
This record is deposited on the Open Science Framework and carries a persistent DOI. Use the links below to locate it in scholarly indexes.
Frenxiv records connect to the wider scholarly record. These services support discovery, identifiers, preservation and open licensing.